Would you recommend adjuvant radiotherapy with concurrent Ado-trastuzumab emtansine (T-DM1) in your breast cancer patients?

In the Katherine trial (von Minckwitz et al. NEJM 2018) 1486 patients with non-metastatic invasive residual HER2+ breast cancer after preoperative chemotherapy were randomized to 14 cycles of trastuzumab or trastuzumab emtasine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic age...

My initial negative experiences with concomitant systemic therapy and breast radiotherapy were in the 1980's with adriamycin for locally advanced breast cancer. In hindsight, this paradigm (which did not persist for a long period) may have resulted from the negative blowback from the preceding well ...